Skip to main content
Equibles
BEAM logo

BEAM · Beam Therapeutics Inc. · Webcasts, Transcripts & Audio

Track BEAM — free

Use BEAM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BEAM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$24.39 +0.00 (+0.00%)
Russell 2000 member Rebalance outlook locked
Market Cap
$2.53B
Shares
103.29M
Volume · Oct 1 1.7M Avg daily vol (3M) 1.98M

Beam Therapeutics Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Beam Therapeutics Inc. (BEAM), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲0% $6,000 −$34.45M '20 Q3 20-11-10 ▲851050% $51.07M −$64.71M '21 Q4 22-01-10 ▼17% $14.27M −$96.67M '24 Q3 24-11-05 LATEST ▲279.5% $114.11M $243.20M '25 Q4 26-02-24
Conference
Investor event
2026-09-08
Beam Therapeutics Inc. (BEAM) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-24
Beam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call Transcript
Confident tone New PKU program (BEAM-304) Sickle cell disease program Platform and predictability
Revenue
$114.11M*
▲ 279.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-05
Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript
Confident tone BEAM-101 / BEACON Phase 1/2 in sickle cell disease ESCAPE antibody-based conditioning platform BEAM-302 in alpha-1 antitrypsin deficiency (AATD)
Revenue
$14.27M
▼ 17% YoY
Diluted EPS
$-1.17
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Beam Therapeutics Inc. (BEAM) Q4 2021 Earnings Call
Revenue
$51.07M*
▲ 851050% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-10
Beam Therapeutics Inc. (BEAM) Q3 2020 Earnings Call
Revenue
$6,000
▲ 0% YoY
Diluted EPS
$-0.69
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–5 of 5 webcasts
Key facts CIK 1745999 CUSIP 07373V105 13F (30d) 7 filings 7 filers Visit website Investor relations